Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment

Asian Journal of Andrology

Volumn 16, Issue 2, 2014, Pages 192-202

  Huhtaniemi, Ilpo ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Hypogonadism; Male ageing; Obesity; Testicular function; Testosterone

Indexed keywords

LUTEINIZING HORMONE; TESTOSTERONE;

AGE; AGING; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANDROPAUSE; CLIMACTERIUM; COMORBIDITY; DEPRESSION; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; HYPOGONADISM; HYPOPITUITARISM; LIFESTYLE MODIFICATION; NOMENCLATURE; OBESITY; PATHOGENESIS; REVIEW; SEXUAL DYSFUNCTION; TESTOSTERONE BLOOD LEVEL; WEIGHT REDUCTION;

AGE OF ONSET; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 84896750181     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122336     Document Type: Review

References (114)

1. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, et al. European male aging study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737-45. (Pubitemid 352008544)
2. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-98. (Pubitemid 34158223)
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-31. (Pubitemid 32207487)
4. Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410-3. (Pubitemid 27172090)
5. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, et al. EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-16.
6. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-35.
7. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl 2009; 32: 1-10.
8. Sun K, Liang GQ, Chen XF, Ping P, Yao WL, et al. Survey for late-onset hypogonadism among old and middle-aged males in Shanghai communities. Asian J Androl 2012; 14: 338-40.
9. Ko YH, Kim JJ. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea. Asian J Androl 2011; 13: 563-8.
10. Tsujimura A, Nonomura N. Recent topics related to testosterone deficiency syndrome in Japan. Asian J Androl 2011; 13: 558-62.
11. Taher A. Proportion and acceptance of andropause symptoms among elderly men: a Study in Jakarta. Acta Med Indones 2005; 37: 82-6.
12. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust 2012; 196: 642-5.
13. Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, et al. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009; 160: 821-31.
14. Carruthers M. Time for international action on treating testosterone deficiency syndrome. Aging Male 2009; 12: 21-8.
15. Saad F. The role of testosterone in type 2 diabetes and metabolic syndrome in men. Arq Bras Endocrinol Metabol 2009; 53: 901-7.
16. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
17. Wylie K, Rees M, Hackett G, Anderson R, Bouloux PM, et al. Androgens, health and sexuality in women and men. Hum Fertil (Camb) 2010; 13: 277-97.
18. Perheentupa A, Huhtaniemi I. Aging of the human ovary and testis. Mol Cell Endocrinol 2009; 299: 2-13.
19. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science 1997; 278: 419-24. (Pubitemid 27454418)
20. Well D, Yang H, Houseni M, Iruvuri S, Alzeair S, et al. Age-related structural and metabolic changes in the pelvic reproductive end organs. Semin Nucl Med 2007; 37: 173-84. (Pubitemid 46517468)
21. Kidd SA, Eskenazi B, Wyrobek AJ. Effects of male age on semen quality and fertility: a review of the literature. Fertil Steril 2001; 75: 237-48. (Pubitemid 32112097)
22. Hassan MA, Killick SR. Effect of male age on fertility: evidence for the decline in male fertility with increasing age. Fertil Steril 2003; 79 Suppl 3: 1520-7. (Pubitemid 36687928)
23. Neaves WB, Johnson L, Porter JC, Parker CR Jr, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab 1984; 59: 756-63. (Pubitemid 14012503)
24. Johnson L, Zane RS, Petty CS, Neaves WB. Quantification of the human Sertoli cell population: its distribution, relation to germ cell numbers, and age-related decline. Biol Reprod 1984; 31: 785-95. (Pubitemid 15184943)
25. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92: 549-55.
26. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76. (Pubitemid 41428540)
27. Belchetz PE, Barth JH, Kaufman JM. Biochemical endocrinology of the hypogonadal male. Ann Clin Biochem 2010; 47: 503-15.
28. Landry D, Cloutier F, Martin LJ. Implications of leptin in neuroendocrine regulation of male reproduction. Reprod Biol 2013; 13: 1-14.
29. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316: 180-6.
30. Hill JW, Elmquist JK, Elias CF. Hypothalamic pathways linking energy balance and reproduction. Am J Physiol Endocrinol Metab 2008; 294: E827-32.
31. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004; 89: 534-43. (Pubitemid 38269854)
32. Moal V, Mathieu E, Reynier P, Malthiery Y, Gallois Y. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques. Clin Chim Acta 2007; 386: 12-9. (Pubitemid 47417956)
33. Rosner W, Vesper H. Endocrine Society, American Association for Clinical Chemistry, American Association of Clinical Endocrinologists, Androgen Excess/PCOS Society, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, et al. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 2010; 95: 4542-8.
34. Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 2010; 121: 513-9.
35. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49: 1381-95. (Pubitemid 36900626)
36. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90: 5928-36. (Pubitemid 41606507)
37. Blair IA. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 2010; 75: 297-306.
38. Wartofsky L, Handelsman DJ. Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab 2010; 95: 5141-3.
39. Bhasin S, Zhang A, Coviello A, Jasuja R, Ulloor J, et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008; 73: 1311-7.
40. Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 2009; 74: 498-503.
41. Legro RS, Schlaff WD, Diamond MP, Coutifaris C, Casson PR, et al. Reproductive Medicine Network. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab 2010; 95: 5305-13.
42. Lee DM, O'Neill TW, Pye SR, Silman AJ, Finn JD, et al. EMAS study group. The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl 2009; 32: 11-24.
43. Huhtaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, et al. EMAS study group. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol 2012; 166: 983-91.
44. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011; 96: 2430-9.
45. Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012; 97: 4030-9.
46. Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007; 67: 853-62. (Pubitemid 350135128)
47. Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. Clin Chem 2008; 54: 458-60. (Pubitemid 351348150)
48. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72. (Pubitemid 30645223)
49. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 2010; 73: 382-8.
50. Huhtaniemi IT, Pye SR, Limer KL, Thomson W, O'Neill TW, et al. European Male Ageing Study Group. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab 2009; 94: 277-84.
51. Huhtaniemi IT, Pye SR, Holliday KL, Thomson W, O'Neill TW, et al. European Male Aging Study Group. Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men. J Clin Endocrinol Metab 2010; 95: 1898-908.
52. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172-81.
53. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-43. (Pubitemid 44833407)
54. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, et al. EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95: 1810-8.
55. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004; 7: 211-8. (Pubitemid 39315125)
56. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-42.
57. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000; 53: 703-11. (Pubitemid 32096681)
58. Chueh KS, Huang SP, Lee YC, Wang CJ, Yeh HC, et al. The comparison of the aging male symptoms (AMS) scale and androgen deficiency in the aging male (ADAM) questionnaire to detect androgen deficiency in middle-aged men. J Androl 2012; 33: 817-23.
59. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012; 14: 251-9.
60. O'Connor DB, Corona G, Forti G, Tajar A, Lee DM, et al. Assessment of sexual health in aging men in Europe: development and validation of the European Male Ageing Study sexual function questionnaire. J Sex Med 2008; 5: 1374-85. (Pubitemid 351803103)
61. Huhtaniemi I, Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat Rev Urol 2011; 8: 335-44.
62. Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, et al. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 2008; 56: 831-9. (Pubitemid 351652412)
63. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-7. (Pubitemid 350074738)
64. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-6. (Pubitemid 39628393)
65. Corona G, Rastrelli G, Maggi M. Diagnostic and treatment of late-onset hypoginadism. Systematic review and meta-analysis of TRT outcomes. Best Pact Expt Clin Endocrinol 2013; 27: 557-79.
66. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009; 21: 1-8.
67. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, et al. EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-55.
68. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844-53. (Pubitemid 47607632)
69. Cunningham GR, Toma SM. Why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011; 96: 38-52.
70. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7: 46-56.
71. Mikhail N. Does testosterone have a role in erectile function? Am J Med 2006; 119: 373-82.
72. Rhoden EL, Teloken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002; 167: 1745-8. (Pubitemid 34240718)
73. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, et al. Aging and pathogenesis of erectile dysfunction. Int J Impot Res 2004; 16: 395-402. (Pubitemid 39319038)
74. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 381-94. (Pubitemid 41442332)
75. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 20-8. (Pubitemid 46036318)
76. Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012; 157: 681-91.
77. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-50.
78. Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013; 98: 1891-900.
79. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72. (Pubitemid 30647018)
80. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502-10. (Pubitemid 40464011)
81. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
82. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci 2003; 58: 1002-8. (Pubitemid 37467297)
83. Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003; 88: 5240-7. (Pubitemid 37452722)
84. Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, et al. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf) 2005; 63: 152-60. (Pubitemid 41097983)
85. O'Connell MD, Roberts SA, Srinivas-Shankar U, Tajar A, Connolly MJ, et al. Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab 2010.
86. Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev 2012; 33: 314-77.
87. Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc 2008; 56: 1991-9.
88. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503-10. (Pubitemid 38269849)
89. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56: M266-72. (Pubitemid 32381803)
90. Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91: 2011-6. (Pubitemid 43854973)
91. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2010.
92. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-83.
93. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011; 96: 2341-53.
94. Angell P, Chester N, Green D, Somauroo J, Whyte G, et al. Anabolic steroids and cardiovascular risk. Sports Med 2012; 42: 119-34.
95. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl 2012; 14: 428-35.
96. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690-6. (Pubitemid 29485250)
97. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-11.
98. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46.
99. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97: 870-5.
100. Malkin CJ, Jones TH, Channer KS. Testosterone in chronic heart failure. Front Horm Res 2009; 37: 183-96.
101. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57-64. (Pubitemid 41785933)
102. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-27.
103. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002; 57: M321-5. (Pubitemid 34464973)
104. Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006; 63: 177-85. (Pubitemid 43261728)
105. Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas 2011; 69: 322-37.
106. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7. (Pubitemid 41798454)
107. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
108. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008; 93: 914-9. (Pubitemid 351398573)
109. Bachman E, Feng R, Travison T, Li M, Olbina G, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab 2010; 95: 4743-7.
110. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299-311. (Pubitemid 39571784)
111. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-93. (Pubitemid 41233445)
112. Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ 2008; 336: 709-13. (Pubitemid 351481214)
113. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 1999; 50: 629-35. (Pubitemid 29236340)
114. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212-5. (Pubitemid 24218140)